Search Results - Andres Cruz‐Herranz

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib... by Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho

Connect to this object online.